BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 19463281)

  • 1. [Clinical use of micafungin for the treatment of invasive candidiasis in critical ill patients].
    Pozo-Laderas JC
    Rev Iberoam Micol; 2009 Mar; 26(1):69-74. PubMed ID: 19463281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Micafungin in invasive candidiasis among oncohematological patients].
    Jarque I; Angel Sanz M
    Rev Iberoam Micol; 2009 Mar; 26(1):75-7. PubMed ID: 19463282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections.
    Cross SA; Scott LJ
    Drugs; 2008; 68(15):2225-55. PubMed ID: 18840009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Future role of micafungin in the treatment of invasive mycoses caused by filamentous fungi].
    Salavert-Lletí M; Zaragoza-Crespo R
    Rev Iberoam Micol; 2009 Mar; 26(1):81-9. PubMed ID: 19463284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Micafungin for therapy of invasive candidiasis in solid organ transplant recipients].
    Fortún-Abete J
    Rev Iberoam Micol; 2009 Mar; 26(1):65-8. PubMed ID: 19463280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of micafungin for the treatment of invasive candidiasis and candidaemia in patients with neutropenia.
    Chandrasekar P; Sirohi B; Seibel NL; Hsu JW; Azie N; Wu C; Ruhnke M
    Mycoses; 2018 May; 61(5):331-336. PubMed ID: 29364548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Why might micafungin be the drug of choice in pediatric patients?].
    Ramos Amador JT; Prieto Tato L; Guillén Martín S
    Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():23-8. PubMed ID: 21420573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species.
    Cornely OA; Vazquez J; De Waele J; Betts R; Rotstein C; Nucci M; Pappas PG; Ullmann AJ
    Mycoses; 2014 Feb; 57(2):79-89. PubMed ID: 23786573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of micafungin for invasive candida infections: a meta-analysis of randomized controlled trials.
    Chen Q; Lin MH; Chen ML; Liu ZY; Chai D; Wang R
    Chin Med J (Engl); 2012 Jan; 125(2):345-51. PubMed ID: 22340571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Micafungin for the treatment of neonatal invasive candidiasis].
    Infante-López ME; Rojo-Conejo P
    Rev Iberoam Micol; 2009 Mar; 26(1):56-61. PubMed ID: 19463278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Echinocandin use in the neonatal intensive care unit.
    Caudle KE; Inger AG; Butler DR; Rogers PD
    Ann Pharmacother; 2012 Jan; 46(1):108-16. PubMed ID: 22190252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients.
    Carter NJ; Keating GM
    Paediatr Drugs; 2009; 11(4):271-91. PubMed ID: 19566111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. De-escalation from micafungin is a cost-effective alternative to traditional escalation from fluconazole in the treatment of patients with systemic Candida infections.
    Masterton RG; Casamayor M; Musingarimi P; van Engen A; Zinck R; Odufowora-Sita O; Odeyemi IA
    J Med Econ; 2013 Nov; 16(11):1344-56. PubMed ID: 24003830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of micafungin for treatment of serious Candida infections in patients with or without malignant disease.
    Cornely OA; Marty FM; Stucker F; Pappas PG; Ullmann AJ
    Mycoses; 2011 Nov; 54(6):e838-47. PubMed ID: 21668522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Micafungin: new drug. Severe candidiasis: a third echinocandin, with life-threatening hepatotoxicity.
    Prescrire Int; 2009 Aug; 18(102):154. PubMed ID: 19743568
    [No Abstract]   [Full Text] [Related]  

  • 16. Refractory neonatal candidemia and high-dose micafungin pharmacotherapy.
    Natarajan G; Lulic-Botica M; Aranda JV
    J Perinatol; 2009 Nov; 29(11):738-43. PubMed ID: 19776753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New options for treatment of candidaemia in critically ill patients.
    Ruhnke M; Hartwig K; Kofla G
    Clin Microbiol Infect; 2008 May; 14 Suppl 4():46-54. PubMed ID: 18430129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Micafungin versus anidulafungin in critically ill patients with invasive candidiasis: a retrospective study.
    van der Geest PJ; Hunfeld NG; Ladage SE; Groeneveld AB
    BMC Infect Dis; 2016 Sep; 16():490. PubMed ID: 27634140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antifungal therapy update: new drugs and medical uses].
    Fortún J
    Enferm Infecc Microbiol Clin; 2011 Dec; 29 Suppl 5():38-44. PubMed ID: 22305668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Micafungin therapy in a critically ill, morbidly obese patient.
    Zomp A; Bookstaver PB; Ahmed Y; Turner JE; King C
    J Antimicrob Chemother; 2011 Nov; 66(11):2678-80. PubMed ID: 21810839
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.